Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study
Nicole Lioufas, Nigel D Toussaint, Eugenia Pedagogos, Grahame Elder, Sunil V Badve, Elaine Pascoe, Andrea Valks, Carmel Hawley, Nigel D Toussaint, Eugenia Pedagogos, Nicole Lioufas, Carmel M Hawley, Grahame J Elder, Elaine M Pascoe, Andrea Valks, Sunil V Badve, Geoffrey A Block, Neil C Boudville, Katrina Campbell, James D Cameron Show all
BMJ Open | BMJ PUBLISHING GROUP | Published : 2019
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by NHMRC Enabling Grant
Awarded by NHMRC Programme Grant
The IMPROVE-CKD study was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia Project Grant (APP1044302); NHMRC Enabling Grant (ID 631731); NHMRC Programme Grant (APP1092957) and Shire Pharmaceuticals Development Limited Clinical Trial Contribution. Study medication (lanthanum carbonate and matching placebo) was supplied by Shire Pharmaceuticals.